Hospitalisations, 2020-21



AOD-related hospitalisations among Australians aged \geq 50 years have increased over the last two decades.



Approximately three in five hospitalisations occurred among males in 2020-2021.

30%

Unintentional

Three in five overdose

hospitalisations were

intentional.

7%

Undetermined

intent

59%



were most common among those aged 50-59 years.

Antiepileptic, sedative-

Non-opioid analgesics

Amphetamine-type

hypnotic and anti-

parkinsonism drugs

79% Alcohol

Opioids

stimulants

The vast majority of all AOD-

related hospitalisations were

attributable to alcohol.


5%

4%


2%

2%


44%27.1



< 1% of alcohol-related hospitalisations were attributable to overdose in 2020-21, with dependence the leading diagnosis (44%).




Percentage Rate per 100,000 Although the majority of hospitalisations occurred in major cities, the rate was highest in remote and very remote areas.




94% Other principal diagnosis

Few alcohol-related deaths were attributable to overdose in 2021, with cardiovascular, digestive and endocrine diseases the leading diagnosis (71%).




Although the majority of deaths occurred in major cities, the rate per 100,00 people was comparable across remoteness areas.




Two-fifths of other drug hospitalisations were attributable to overdose in 2020-2021.

Deaths, 2021




AOD-induced deaths among Australians aged \geq 50 years have increased slightly over the past two decades.



The majority of other drugrelated deaths were attributable to overdose.




Approximately two in three deaths were male.




61% Unintentional 34% Intentional 6% Undetermined intent

In 2021, most overdose deaths were unintentional.



Opioids, and antiepileptic, sedative-hypnotic and antiparkinsonism drugs were the most common drug types involved in drug overdose deaths.

Treatment, 2021






Treatment episodes among Australians aged \geq 50 years have increased over the past two decades.

68%

Approximately three in five people entering treatment were male.



The rate of people entering treatment for amphetamines has increased 23-fold over the past two decades.





Although the majority of treatment episodes occurred in major cities, the rate per 100,00 people was highest in remote and very remote areas.


Use, 2022/23

Alcohol


Opioids

Amphetamines


Cannabinoids









Alcohol was the most common substance that Australians aged \geq 50 years reported using in the past year.




Past year AOD use was comparable among males and females.



Past year cannabis use increased three-fold between 2001 and 2022/23.



Past year AOD use was lowest among those aged ≥ 80 years.



30% of Australians aged \geq 50 years reported exceeding Australia's drinking guidelines, with this being highest among those aged 50-69 years.

9%

8%

7%

Alcohol was the most common drug that

people were entering treatment for.

Priority groups Men:



Males had higher rates of AOD-induced deaths and AOD-related hospitalisations compared to females, which remained consistent across age-groups and remoteness areas.

Older adults who use opioids

and/or benzodiazepines:

People aged 50-59 years:

Older adults who use alcohol:



People aged 50-59 years consistently had higher rates of AOD-related harms, compared to those aged ≥60 years.

Older adults who use cannabis:



Alcohol was by the far the most commonly used substance by people aged ≥50 years, with almost one in three exceeding drinking guidelines. The majority of AODrelated hospitalisations and treatment episodes were attributable to alcohol.

Older adults who use amphetamine-type stimulants:



Opioids and antiepileptic, sedativehypnotic and anti-parkinsonism drugs (e.g., benzodiazepines) were the most common drugs involved in drug overdose deaths.



Past year cannabis use tripled between 2001 and 2022/23, with a five-fold increase in people entering treatment for cannabis.



Substantial increases in hospitalisations, overdose deaths and treatment episodes were observed for amphetamine-type stimulants over the past two decades.

Risk factors

Location:



Most harms related to illegal or prescription drugs were largely the result of overdose, and occurred at home.

Remoteness areas:



Rates of hospitalisations, deaths and treatment episodes were highest in remote and very remote areas.

Polysubstance use:



In 2021, two-thirds of AODinduced deaths involved >1 drug class, although this was less common in AOD-related hospitalisations.

Psychosocial risk factors:



Personal history of self-harm was the most common risk factor in both intentional and unintentional.